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SUMMARY
The objective of this study is to identify subtypes of Human Immunodeficiency Virus type 1 (HIV-1) and to analyze the presence 
of mutations associated to antiretroviral resistance in the protease (PR) and reverse transcriptase (RT) regions from 48 HIV-1 positive 
treatment naïve patients from an outpatient clinic in Maringá, Paraná, Brazil. Sequencing was conducted using PR, partial RT and 
group-specific antigen gene (gag) nested PCR products from retrotranscribed RNA. Transmitted resistance was determined according 
to the Surveillance Drug Resistance Mutation List (SDRM) algorithm. Phylogenetic and SimPlot analysis of concatenated genetic 
segments classified sequences as subtype B 19/48 (39.6%), subtype C 12/48 (25%), subtype F 4/48 (8.3%), with 13/48 (27.1%) 
recombinant forms. Most recombinant forms were B mosaics (B/F 12.5%, B/C 10.4%), with one C/F (2.1%) and one complex B/C/F 
mosaic (2.1%). Low levels of transmitted resistance were found in this study, 2/48 (2.1% to NRTIs and 2.1% for PI). This preliminary 
data may subsidize the monitoring of the HIV evolution in the region.
KEYWORDS: Primary resistance; Transmitted resistance; HIV-1; Naïve patients; Subtypes; Brazil.
INTRODUCTION
In Brazil, 492,581 cases of AIDS were identified between 1980 and 
2010. The prevalence of HIV in the population is estimated to be around 
0.6%. The distribution of the cases according to regions, in 2009, showed 
that 38.2% of the cases are in the southeastern region, followed by the 
northeast (21.9%), south (21.1%), north (11.1%) and center-west (7.7%). 
Although more cases were recorded in the southeastern region, the south 
has a higher prevalence of AIDS cases, 12.6/100,000 inhabitants. The 
city of Maringá, situated in the north-central part of the State of Paraná, 
had 34.9 reported cases of AIDS per 100,000 inhabitants in 20093. In 
2010, a total of 201,279 patients were receiving antiretroviral therapy in 
Brazil, 45,308 in the south region and 10,821 in Paraná4. 
In newly infected individuals, treatment may be compromised because 
of the possibility of transmission of viral variants that are resistant to 
antiretroviral drugs, from some treated patients who had been exposed to 
antiretrovirals44. Several studies involving antiretroviral treatment-naïve 
patients have been conducted independently in different Brazilian cities, 
and the reported rates of primary resistance range from 1.4 to 8.3%7,10,20. 
The first large-scale evaluation of HIV diversity and transmitted resistance 
that included samples from southern Brazil, including Rio Grande do Sul 
(n = 139) and Paraná (n = 147), showed prevalence rates of 44.88% and 
29.79% for subtype C, 29.92% and 63.83% for B, 3.15% and 4.26% for 
F, and 22.05% and 21.3% for recombinant forms, respectively8.
The present study analyzed sequences of the protease, reverse 
transcriptase and gag genes for the evaluation of HIV-1 viral subtypes and 
the identification of mutations/polymorphisms related to antiretroviral 
resistance among treatment-naïve patients seen at the STD/AIDS 
Specialty Clinic in the city of Maringá, Paraná, Brazil.
MATERIALS AND METHODS
Study population: HIV-1-positive treatment-naïve patients (n = 
61) seen at the STD/AIDS Specialty Clinic in Maringá, from April 
through June 2009 were invited to participate in this study. The study 
was approved by the Ethics Committee on research involving humans of 
the Universidade Estadual de Maringá (CAAE No. 0047.0.093.000-09; 
protocol 126/2009), and written informed consent was obtained from each 
patient. Sociodemographic data were collected from the patient records.
Calculation of sample size: The sample size was defined in 
accordance with the protocol of the World Health Organization (WHO) 
HIV Drug-Resistance Threshold Survey (HIV DR THS)27.
CD4+ and CD8+ T cell counts and quantification of HIV-1 
RNA: The number of CD4+ and CD8+ T cells was determined by flow 
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cytometry (BD TrucountTM Tubes) in a FACSCalibur flow cytometer 
(Becton-Dickinson, New Jersey, USA). Viral load was evaluated by the 
branched DNA assay (VERSANT® HIV-1 RNA 3.0 Assay) in a 340 
bDNA Analyzer (Bayer HealthCare, New York, USA) according to the 
manufacturer’s instructions. The quantification limit of the assay ranges 
from 50 to 500,000 copies/mL plasma.
RNA extraction and synthesis of cDNA: HIV-1 RNA was extracted 
using the QIAmp® Viral RNA Mini Handbook extraction kit (QIAGEN, 
Courtaboeuf, France). cDNA was retrotranscribed using superscript II 
(Invitrogen, USA).
Amplification of the PR/RT region: In the first step of the nested 
PCR, a partial Pol gene was amplified using the K1 and K2 primers (PR/
RT, 1,200 bp)22. The second reaction allowed us to amplify regions of 
the complete PR and RT genes, separately. The DP10 and DP11 primers 
(400 bp)31 were used to amplify the protease region, and the F1 and F2 
primers (800 bp)16 to amplify the RT region. 
Amplification of the gag gene: In the first step of the nested PCR, 
the H1G777 and H1P202 primers12 were used to amplify a region of 
the gag gene (1,100 bp). The second step of the nested PCR amplified 
a fragment encoding p24 (460 bp). The H1gag1584 and g17 primers12 
were used for this amplification. 
Sequencing: The PCR products were sequenced as described 
previously33 using the following primers: G17 and H1gag1584 for the 
gag gene, DP10 and DP11 for the protease gene, and F1 and F2 for 
the RT gene. Sequencing was carried out using fluorescent-labeled 
dideoxynucleotides (ddNTPs) and the ABI Prism BigDyeTM Terminator 
Ready Reaction Cycle Sequencing kit, version 3.1 (Applied Biosystems, 
Foster City, CA, USA). After precipitation of the reaction product, the 
samples were denatured and sequenced in an automated ABI 3100 
sequencer (Applied Biosystems).
Sequence analysis: The sequences obtained were first analyzed 
using the Phred-Phrap program (http://asparagin.cenargen.embrapa.br/
phph/) for assessment of data quality and construction of the consensus 
sequences using bases with a score > 2039. The sequences were aligned 
with the Muscle program, version 3.614 and edited using the Bioedit 
Sequence Alignment Editor, version 7.0.9.019. The phylogenetic signal 
was obtained with the DAMBE program, version 5.0.3242, and genetic 
diversity and distance were calculated with the MEGA 4 program 
(Molecular Evolutionary Genetics Analysis)38. The Tamura-Nei model 
was used for signal and diversity calculations, while the Kimura two-
parameter model was employed in the distance analysis. To increase the 
gag phylogenetic signal, PR and RT sequences from each patient were 
concatenated using MS Excel and BioEdit software. Subtypes were 
screened with the REGA HIV-1 Subtyping tool (http://www.bioafrica.net/
rega-genotype/html/subtypinghiv.html)28 and NCBI genotyping (http://
www.ncbi.nlm.nih.gov/projects/genotyping/formpage.cgi)32, while 
phylogenetic reconstruction, performed with PAUP* 4.10b software37, 
and bootscanning (SimPlot version 3.5.125) employing a 200-bp window 
and a 20-bp stepsize, using 500 replicates, were used to confirm subtypes 
and unique recombinant forms (URF), respectively. Neighbor-Joining 
(NJ) and Maximum Likelihood (ML) trees were obtained using the 
GTR+i+g model as determined using ModelTest3.7. Bootstrap values 
were obtained using 1000 replicates to test the reliability of the tree. 
The reference sequences were obtained from the Los Alamos National 
database.
Algorithms used for the analysis of resistance-associated 
mutations and polymorphisms: To classify and identify polymorphisms 
and mutations associated with resistance to ARVs, the FASTA sequences 
of the PR and RT were analyzed using the freely available SDRM-2009 
algorithm available in the Calibrated Population Resistance tool (CPR), 
version 6.0 beta (http://cpr.stanford.edu/cpr/servlet/CPR)17. The SDRM 
algorithm was applied to determine the prevalence of primary ARV 
resistance mutations, using a list of drug-resistance mutations that provide 
an estimate of resistance transmission according to the WHO guidelines. 
Statistical analysis: Data were analyzed using the STATISTICA 
7.135 and Open Source Epidemiologic Statistics for Public Health 
(OpenEpiversion 2.311) programs. The χ2 test and Fisher’s exact test 
were used to compare categorical variables, and ANOVA was applied 
to compare continuous variables. A p value < 0.05 was considered to be 
statistically significant.
RESULTS
Samples from 61 patients were submitted to PR, RT and gag PCR. Of 
these, the PR and RT regions were amplified in 48 (78.7%) and the gag 
gene in 46 (75.4%), and these isolates were sequenced. Sociodemographic 
and baseline characteristics of the patients are summarized in Table 1. 
Sequences analysis of the 48 isolates for subtype classification 
showed that subtypes B (n = 19, 39.6%) and C (n = 12, 25%) were 
the most prevalent, followed by subtype F (n = 4, 8.3%) (Fig. 1). 
The frequency of recombinant forms was 27.1% (n = 13), including 
subtypes B/F in six (12.5%), B/C in five (10.4%) and F/C in one (2.1%). 
One complex genome, possibly including genomes B/C/F, was also 
observed (2.1%). 
The gag region was not amplified in two isolates classified as subtype 
B according to both the PR and RT regions, and considered here as B 
(Table 2). The HIV-1 genetic distance was 9.2 ± 0.7% for RT, 9.5 ± 1.0% 
for PR and 10.2 ± 1.1% for gag. 
Table 3 shows the epidemiological data for the 48 treatment-naïve 
patients according to viral subtype. Statistical analysis revealed a 
significant difference in viral load, with higher values being observed in 
patients harboring recombinant forms of the virus (p < 0.01). Although the 
difference was significant, a broader evaluation is necessary to confirm 
the biological significance of our findings. Quantification of CD4+ T cells 
showed no statistically significant difference (p = 0.773). 
According to the SDRM algorithm, the prevalence of primary 
resistance mutations was 4.2%, with 2.1% to PIs (V82L and L90M) and 
2.1% to NRTIs (K219N). Both mutations detected in the protease region 
belonged to a single patient. 
The protease polymorphisms most frequently found in the 48 isolates 
sequenced were M36I (62.5%), I15V (60.4%), L63P (43.7%), E35D 
(35.4%) and L10I/V (8.3%). The most frequent RT polymorphisms were 
R211K (58.3%), V35T (45.8%), K122E (41.6%), Q207E (35.4%), I135T 
(33.3%) and V118I (6.2%).
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DISCUSSION
This study describes HIV-1 molecular epidemiology findings from 
Maringá, Paraná. Although many studies have treated this subject, few 
were conducted outside major cities, and this is the first to describe the 
situation in this region. We assessed 61 antiretroviral-naïve patients from 
the local AIDS clinic, and succeeded in obtaining molecular data from 
48 (79%). The main factor associated with failure of PCR amplification 
was a low plasma viral RNA load. With a mean plasma viral load of 4.2 
(± 0.7) log10/mL among the 48 patients who were successfully evaluated, 
patients with sequences that were not amplified in this study showed a 
mean number of viral RNA copies (log10) of 3.0 (± 1.6)/mL plasma (< 
50 to 171,563 RNA copies/mL plasma). Ten of the 13 non-amplified 
isolates contained < 5000 RNA copies/mL plasma.
Subtype C was detected in 25%; other studies analyzing samples from 
patients of the southern region have observed similarly high prevalences 
of subtype C7,8,24,34. For instance, a study conducted in Santa Catarina (n 
= 80) reported a high prevalence of subtype C (48.75%), which increased 
to 71.25% when the recombinant viruses containing subtype C-related 
sequences were included in the analysis24. In a study with samples from 
a voluntary testing site in Curitiba, Paraná, FERREIRA et al.15 detected 
subtype B in 52.6% of cases, followed by subtype C in 29.8%, mosaic 
BC in 14%, CF in 1.8%, and F in 1.8%. Subtype C was the most prevalent 
(29%) in a study conducted in 2008 in Porto Alegre, Rio Grande do Sul. 
Subtype B was detected in 22.6% of the patients, followed by CRF_31BC 
in 23.4%, subtype F in 10% and other mosaic forms in 5.5%13. 
In the present study, the frequency of recombinant forms was 
27.1%: B/F (12.5%), B/C (10.4%) and F/C (2.1%), i.e., a relatively high 
proportion. Similarly high proportions have been documented in studies7 
in other areas of Brazil. This probably indicates that different subtypes 
have co-circulated for some time, especially subtypes B and C in our 
area, with no segregation of subtype by risk group. This theoretically 
increases the probability of co-infection and occasional recombination of 
different subtypes. Our study assessed mostly heterosexual cases, and our 
sample was limited, so it is not possible to confirm this hypothesis. Larger 
and appropriately designed studies are necessary to evaluate this issue.
The number of CD4+ T cells showed no relationship with the various 
subtypes, and the differences observed in the viral load may be due to 
intra-patient variations in infected individuals. Therefore, the small 
number of samples in our study does not allow an adequate assessment 
of this problem. More studies are needed to clarify this important issue. 
The follow-up of these patients will assess whether the decrease in CD4+ 
T cells and the need for treatment may help to better understand this issue. 
None of the recombinant forms showed a clear phylogenetic 
relationship or breakpoint structure suggestive of the known CRFs. Three 
of the recombinants (SGS61, LAM60 and WDNS28) have a similar 
Table 1
Sociodemographic data of the 61 HIV-1-positive antiretroviral treatment-naïve patients monitored between April and June 2009 at the  
STD/AIDS Specialty Clinic of the city of Maringá, Paraná
 Gender
Total
(n = 61)
Female
(n = 25)
Male
(n = 36)
Age (years)1
Mean (standard deviation) 35.6 (± 10.9) 37.4 (± 11.1)  34.4 (± 10.7)
Median (range) 35.0 (15.0 – 61.0) 36.0 (17.0 – 61.0) 35.0 (15.0 – 59.0)
Viral load (RNA copies/mL)2
Mean (standard deviation) 39,664.0 (± 58,803.2) 30,530.4 (± 50,034.6) 46,006.8 (± 64,109.7)
Median (range) 15,122.0 (50.0 – 215,745.0) 15,122.0 (70.0 – 190,374.0) 13,696.5 (50.0 – 215,745.0)
CD4+ T cell count (cells/mm3)3
Mean (standard deviation) 492.57 (± 259.54) 494.68 (± 258.99) 491.11 (± 263.58)
Median (range) 473.0 (3.0 – 1,058.0) 515.0 (14.0 – 965.0) 466.0 (3.0 – 1.058.0)
CD8+ T cell count (cells/mm3)4
Mean (standard deviation) 1,095.8 (± 562.7) 860.3 (± 448.5) 1,259.3 (± 581.2)
Median (range) 982.0 (65.0 – 2,874.0) 862.0 (238.0 – 2,429.0) 1,122.5 (65.0 – 2,874.0)
Ethnic origin5
Caucasian 51 21 30
Afro-descendant 8 4 4
Asian 2 0 2
Exposure category6
Heterosexual 48 25 23
Men having sex with men 12 0 12
Bisexual 1 0 1
1p = 0.201; 2p = 0.861; 3p = 0.105; 4p = 0.950; 5p = 0.532 ; 6p < 0.01.
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breakpoint structure, cluster in the phylogenetic tree, and may represent 
a new CRF. The same was observed with two sequences of a different 
pattern (MABC56 and MRR20) as shown in Figure 2. To confirm this, 
epidemiological information, as well as a nearly full-length sequence 
would be necessary to assign a new CRF to those isolates. 
The mutations in the SDRM list were selected as indicators of 
resistance transmission according to the following criteria: (i) recognized 
as the cause of or as contributing to resistance, (ii) non-polymorphisms 
in untreated patients and (iii) applicable to all HIV-1 subtypes17. The 
prevalence of ARV-transmitted resistance observed in this study (4.2%) 
Table 2
Distribution of HIV-1 subtypes isolated from antiretroviral treatment-naïve 
patients (n = 48) monitored between April and June 2009 at the STD/AIDS 
Specialty Clinic of the city of Maringá, Paraná
HIV-1 Subtype n (%)
B 19 (39.6)
C 12 (25)
F 4 (8.3)
B/F 6 (12.5)
B/C 5 (10.4)
C/F 1 (2.1)
B/C/F 1 (2.1)
Total 48 (100)
Fig. 1 - Neighbor-Joining phylogenetic reconstruction obtained using Paup* 4.10b software 
and the GTR+i+g evolutionary model. Concatenated sequences of partial gag/PR/RT HIV-1 
genes obtained from patients (n = 48*) of the 15th Regional Health District of the State of 
Paraná (Maringá) were included, as well as pure subtype reference sequences downloaded 
from Los Alamos reference dataset. The subtype O sequence [OSEMP1300_1999_AJ302647] 
was used as outgroup. Recombinant sequences are illustrated with a ∆ symbol. 
Fig. 2 - HIV-1 sequence approximate breakpoint positions (according to HXB2 reference) 
of recombinant mosaics at the partial gag and pol regions from Maringá-PR sequences, as 
deduced according to SimPlot Bootscanning analysis (200 bp window; 20 bp step size; 500 
replicates). Sequences MABC56 and MRR20 showed a similar recombinant pattern, sharing 
breakpoints with CRF31BC, however with no subtype similarity between sequences and CRF. 
Sequences SGS61, LAM60 and WDNS28 shared the same recombinant pattern, with strong 
bootscan values (> 90) between them. U represents an undefined subtype.
was comparable to that reported by SPRINZ et al.34, who investigated 
387 treatment-naïve patients from 13 Brazilian cities (Ribeirão Preto, 
Santo André, Santos, Nova Iguaçu, Rio de Janeiro, Belo Horizonte, 
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Curitiba, Florianópolis, Salvador, Brasília, Campinas, Porto Alegre and 
São Paulo) and found that 6.7% of the mutations conferred resistance to 
ARVs. The prevalence of transmitted resistance according to drug class 
was 1% for PIs, 4.4% to NNRTIs and 1.3% to NRTIs in that study. In 
another evaluation, FERREIRA et al.15 observed a similar resistance rate 
of 8.8% (7% to NNRTIs and 1.8% to NRTIs).
Among mutations in the RT gene, the K219N mutation identified 
in one patient is associated with low-level resistance to the NRTIs 
zidovudine (AZT) and stavudine (D4T). This mutation was detected 
in the recombinant isolate Fgag/FPR/BRT. Related mutations were found 
in treatment-naïve patients from Venezuela, for example, K219R in 
a recombinant virus Cgag/BRT/CENV 9 and K219Q, a thymidine-analog 
mutation2.
According to the Stanford algorithm17, mutation V118I, which 
was found in three patients in this study, causes low-level resistance to 
lamivudine (3TC) and possibly to other NRTIs in the presence of mutation 
E44D and/or thymidine-analog mutations21,40. However, according to 
the Stanford algorithm, this mutation may reduce the activity of 3TC, 
emtricitabine (FTC), AZT, D4T, didanosine (DDI) and tenofovir (TDF), 
as observed in approximately 2% of treatment-naïve patients. 
Mutations that confer resistance to PIs, V82L and L90M were 
detected in the same patient. In the study of YAOTSÈ et al.43, the 
mutation L90M in the protease gene was found to confer resistance to 
the PIs nelfinavir (NFV), indinavir (IDV) and saquinavir (SQV). This 
mutation was also observed in the present study. On the other hand, 
mutation V82L is a rare mutation selected by tipranavir (TPV), which 
reduces susceptibility to the drug. The effect of this mutation on other 
PIs has not been characterized1. 
The minor mutation L10I/V is associated with resistance to most PIs 
when other mutations are present. This mutation is detected in 5-10% of 
untreated patients according to the Stanford database, and reduces the 
activity of the PIs atazavir/ritonavir (ATV/r), fosamprenavir/r (FPV/r), 
IDV/r, lopinavir/r (LPV/r), NFV and SQV/r. The L10I/V polymorphism 
is a mutation that is weakly associated with a reduced response of the 
virus to some PIs26. The combination of minor mutations M36I and 
L10I/V has been suggested to result in the subsequent development of 
mutation L90M, causing virological failure and some level of resistance 
to all PIs29,36.
Theoretically, patients with a recent infection are more prone to 
harbor variants of resistant HIV strains than are chronically infected 
Table 3
Distribution of the epidemiological data of the 48 HIV-1-positive treatment-naïve patients monitored between April and June 2009 at the  
STD/AIDS Specialty Clinic of the city of Maringá, Paraná, according to viral subtype
  HIV-1 Subtype
Total
(n=48)
B
(n=19)
C
(n=12)
F
(n=4)
B/F
(n=6)
B/C
(n=5)
F/C
(n=1)
B/C/F
(n=1)
Years of age1
Mean 35.1 35.7 33.2 37 35.7 31 49 42
Standard deviation (+) 11.2  14.3 9.0 7.2 8.6 9.6 - -
Gender (%)2
Female 20 (41.7%) 6 (31.6%) 6 (50%) 2 (50%) 3 (50%) 3 (60%) 0 0
Male 28 (58.3%) 13 (68.4%) 6 (50%) 2 (50%) 3 (50%) 2 (40%) 1 (100%) 1 (100%)
Exposure category (%)3
Heterosexual 39 (81.2%) 14 11 2 6 4 1 1
Men having sex with men 8 (16.7%) 5 1 1 0 1 0 0
Bisexual 1 (2.1%) 0 0 1 0 0 0 0
CD4+T cell Count (cells/mm3)4 
Mean 474.7 477.3 508.3 463.7 503.8 461.2 382 54
Standard deviation (+) 244 263.4  123.6 97.6 255.1  453.4 - -
CD8+T cell Count (cells/mm3)5 
Mean 1,158.60 1,178.8 1,114.4 1,314.50 1,337.3 978.6 1,094 572
Standard deviation (+) 596.7  618.8  586.4  266.4  860.2  573.8 - -
Viral load (RNA copies/mL)6
Mean 43,571.50 26,395.7 19,142.8 23,219.70 101,732.2 100,229.6 1,832 153,946
Standard deviation (+) 60,061.5 30,759.1  22,771.9 16,505.30  91,567.3  99,219.8 - -
Ethnic origin (%)7
Caucasian 43(89.6%) 18 10 4 4 5 1 1
Afro-descendant 3 (6.2%) 1 1 0 1 0 0 0
Asian 2 (4.2%) 0 1 0 1 0 0 0
1p = 0.812; 2p = 0.738; 3p = 0.229; 4p = 0.773; 5p = 0.902; 6p < 0.01; 7p = 0.892. 
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treatment-naïve patients. This can be explained by the fact that wild-type 
strains become predominant in the absence of selective pressure from a 
drug, when individuals are infected with both wild-type and mutant viral 
strains1. However, drug-resistance mutations can be identified in patients 
with chronic infections, demonstrating the lack of complete reversal in all 
cases and the persistence of these strains in the plasma of treatment-naïve 
patients for several years6,18,23,30. In addition, the possibility of transmission 
of more complex patterns should be taken into account, although they 
are not detected in treatment-naïve patients because of the reversal of 
mutations or because of the low sensitivity of the drug-resistance test 
in detecting variants present in smaller numbers30. In the present study, 
although no patients with recent infection could be identified, resistance 
mutations were detected in patients who had been diagnosed more than 
one year previously.
European protocols recommend resistance testing for all treatment-
naïve patients with acute or recent infections, whereas chronically 
infected patients who require treatment should be tested if the suspicion of 
resistance is high or if the prevalence of resistance in the population exceeds 
10%1,41. In Brazil, resistance testing is recommended only for patients 
undergoing antiretroviral treatment who present virological failure5. The 
low prevalence of resistance mutations in our population does not support 
a recommendation of testing all cases prior to initiating therapy in our area.
In conclusion, HIV-1 subtypes B (39.6%) and C (25%) were the most 
prevalent in Maringá, with a rather high prevalence of recombinants. If 
one considers sequences with one or more segments of subtype C, the 
proportion of B and C is more comparable. Further studies should be 
conducted in the region to monitor the evolution of the epidemic, to 
evaluate the trends both in subtype distributions and in the antiretroviral-
resistance mutation levels. 
Sequence Data: The acession numbers of 142 HIV-1 sequences 
obtained in this study are as follows: HM752101 - HM752242.
RESUMO
Diversidade genética e resistência primária entre pacientes  
HIV-1-positivos de Maringá, Paraná, Brasil
O objetivo foi identificar subtipos do Vírus da Imunodeficiência 
Humana tipo-1 (HIV-1) e analisar a presença de mutações/polimorfismos 
nas regiões da protease (PR) e transcriptase reversa (TR) de 48 pacientes 
virgens de tratamento atendidos no município de Maringá, Paraná, Brasil. 
O sequenciamento foi conduzido usando produtos de nested PCR dos 
genes da PR, TR parcial e group-specific antigen gene (gag) de RNA 
retrotranscrito. A interpretação da resistência transmitida foi realizada 
segundo o algoritmo Surveillance Drug Resistance Mutation List 
(SDRM). As análises filogenética e SimPlot dos segmentos concatenados 
classificaram as sequências como subtipo B 19/48 (39,6%), subtipo 
C 12/48 (25%), subtipo F 4/48 (8,3%), com 13/48 (27,1%) formas 
recombinantes. A maioria das formas recombinantes era mosaicos B (B/F 
12,5%, B/C 10,4%), com um C/F (2,1%) e um mosaico complexo B/C/F 
(2,1%). A prevalência de resistência transmitida foi de 4,2% (2,1% para 
ITRN e 2,1% para IP). Baixos níveis de resistência transmitida foram 
encontrados nesse estudo, 2/48 (2,1% para INTR e 2,1% para IP). Esses 
achados, embora preliminares, podem contribuir no monitoramento da 
epidemia de HIV na região.
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